• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Executive Moves: Novavax

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Catalent Biologics Completes Madison Expansion
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Ensuring Pharma Manufacturing Quality

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion

    Ascendia Pharmaceuticals Poised for Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    Quotient Sciences

    Adare Pharma Solutions

    Alcami

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane

    Aphena Pharma Solutions

    Syngene

    Quotient Sciences

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    FDA cGMP Inspections Amid COVID-19 Pandemic

    Despite FDA's postponement of most facility inspections, the pharma manufacturing industry should be prepared for heightened scrutiny as this crisis develops.

    FDA cGMP Inspections Amid COVID-19 Pandemic
    John J. Carney, Lee H. Rosebush, Susrut A. Carpenter, Andrew M. Serrao, BakerHostetler04.22.20

    In an unprecedented time amid the global COVID-19 pandemic, an increasing number of pharmaceutical manufacturers and developers of active pharmaceutical ingredients are involved in the potentially life-saving development of medications and medical devices. It is more critical than ever that these companies operate under the highest production standards in compliance with Current Good Manufacturing Practice (cGMP) regulations. Despite last month’s Food and Drug Administration (FDA) announcements to postpone most foreign facility inspections1 and all domestic routine surveillance facility inspections,2 the global pharmaceutical manufacturing industry should be prepared for heightened government scrutiny and an onslaught of FDA cGMP inspections as this crisis develops.

    cGMP Regulations Generally

    The Food, Drug, and Cosmetic Act (FDCA)3 prohibits adulterated and misbranded products from being manufactured, sold, or transported via interstate commerce.4 A drug or medical device is adulterated if “the methods used in, or the facilities or controls used for, its manufacture, processing, or holding do not conform to … current good manufacturing practice.”5 The applicable cGMP regulations are codified in Parts 210, 211, and 212 of Title 21 of the Code of Federal Regulations and are further defined by the FDA in applicable guidance documents. The FDA ensures the quality of drug products by carefully monitoring manufacturers’ compliance with cGMP.

    The main cGMP components require manufacturers to ensure quality and reliability of their finished products. Quality control, sanitation and hygiene, environmental monitoring, facility management, equipment, raw materials, personnel, and accurate record-keeping are key factors in maintaining cGMP compliance.

    FDA’s Potential Focus During Inspections

    During the COVID-19 pandemic, the FDA will likely focus during an inspection on a facility’s sanitary conditions and the health and hygiene of the facility’s employees. Pharmaceutical manufacturers, therefore, should thoroughly review policies regarding symptomatic presentations, potential COVID-19 infections, sterilization, and associated reporting. For example, cGMP regulations detail personnel hygiene responsibilities such as:

    • Wearing clean clothing and protective apparel;6
    • Practicing good sanitation and health habits;7
    • Establishing limited-access rules for certain facility areas;8
    • Excluding any employee with an apparent illness that may adversely affect the safety or quality of drug products from direct contact with components, drug product containers, in-process materials, and drug products until the employee regains full health;9 and
    • Reporting of all health conditions that may have an adverse effect on drug products.10

    The FDA will also focus on data integrity during cGMP inspections, which ensures all data regarding the “safety, efficacy, and quality of drugs” is “reliable and accurate.”11 In the context of COVID-19, the FDA will be interested in reviewing the records surrounding the development of possible treatments and other drugs that are globally in short supply. cGMP data integrity requirements include:

    Computer output to “be checked for accuracy” and “backup data are exact and complete and … secure from alteration, inadvertent erasures, or loss”;12

    Documenting certain activities “at the time of performance”;13 and

    Data to be “stored to prevent deterioration or loss.”14

    Consequences for Non-Compliance

    At the conclusion of an inspection, if an inspector observes a violation, then the FDA may issue a warning letter or an FDA Form 483. A Form 483 sets forth the inspector’s observations of potential regulatory violations and could lead to expensive disruption and remediation efforts for a company. A company must respond to a Form 483 in writing within 15 days with a corrective action plan and implement its plan promptly. Failure to remedy violations observed in a Form 483 could result in subsequent enforcement actions against the company.

    Additionally, warning letters are formal FDA notifications that identify serious violations. They signal that the FDA is prepared to begin a court proceeding unless the company quickly and extensively remediates its violations. Most warning letters demand that the recipient take specific measures to correct the violations and provide a plan to prevent future violations.

    The FDA also has other types of enforcement actions at its disposal. It could commence product seizures, taking an action against an adulterated product to remove specific violative goods from commerce. The FDA could also consider withholding or withdrawal of product approvals, civil injunction proceedings, civil monetary penalties, and debarment of individuals from future employment by FDA-regulated companies. Tangentially, public companies can also face inquiries and enforcement penalties from the Securities and Exchange Commission for insufficient disclosures of adulterated products and related FDA inspections.

    A major consideration for pharmaceutical companies is the False Claims Act (FCA). The FCA has implications for CGMP violations because the United States is one of the largest purchasers of prescription medications. Per the FCA, individual whistleblowers can commence investigations under the Qui Tam provisions. Because the FCA imposes liability on any government contractor that knowingly submits false claims to the United States, a pharmaceutical manufacturer that was aware or should have been aware of a cGMP-compromised manufacturing process is likely liable under the FCA. Specifically considering the data integrity cGMP rules mentioned above, substantial cGMP violations that are not documented properly, are covered up or are otherwise misrepresented could trigger FCA liability.

    The FDA can even seek criminal prosecution by referring a matter to the Department of Justice. In such instances where the appropriate crime is a misdemeanor violation of the FDCA, a conviction does not require proof of criminal intent. Under the Responsible Corporate Officer Doctrine, also known as the “Park Doctrine” after United States v. Park,15 a company’s officer may be criminally liable for a violation without criminal intent or even awareness of the violation. As the United States Supreme Court explained in Park, a violation attaches “not only to those corporate agents who themselves committed the criminal act, but also to those who by virtue of their managerial positions or other similar relation to the actor could be deemed responsible for its commission.”16

    Takeaways

    In the face of such serious consequences for non-compliance with these FDA regulations, companies should be committed – and should have been committed even before COVID-19 – to bringing processes into compliance before an FDA inspection. Those companies that received a Form 483 should be considering stricter programs to remedy a potential violation. Moreover, if an inspection does reveal any cGMP issue or violation, it is crucial to execute a rapid and thorough response.

    In the time of COVID-19, however, companies should make specific adjustments. This includes conducting internal audits of cGMP compliance and increased scrutiny in specific areas that may relate to COVID-19. For example, companies should consider training their employees on preventing the spread of disease and providing them regular updates on COVID-19 developments. It may also be necessary to institute stricter protocols for hygiene, employee health, equipment sanitation, and even employee quarantines.

    Being well versed in cGMP policies, compliance guidelines, and government enforcement priorities and protocols is critical. If a pharmaceutical company suspects that it might need assistance dealing with a government inquiry or, as a preventive measure, wants to conduct a review of its compliance programs and cGMP processes, the company may wish to seek out those that are well equipped to make assessments and advise as to the best course of action.

    References
    1 - Coronavirus Disease 2019 (COVID-19) Update: Foreign Inspections, U.S. Food & Drug Administration (Mar. 10, 2020), https://www.fda.gov/news-events/press-announcements/coronavirus-disease-2019-covid-19-update-foreign-inspections.
    2 -  Coronavirus (COVID-19) Update: FDA Focuses on Safety of Regulated Products While Scaling Back Domestic Inspections, U.S. Food & Drug Administration (Mar. 18, 2020), 
    https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-focuses-safety-regulated-products-while-scaling-back-domestic.
    3 -  21 U.S.C. § 301 et seq.
    4 -  See 21 U.S.C. § 351.
    5 -  21 U.S.C. § 351(a)(2)(B).
    6 - 21 C.F.R. § 211.28(a).
    7 -  21 C.F.R. § 211.28(b).
    8 -  21 C.F.R. § 211.28(c).
    9 -  21 C.F.R. § 211.28(d).
    10 - 21 C.F.R. § 211.28(d).
    11 -  Data Integrity and Compliance With Drug CGMP Questions and Answers Guidance for Industry, U.S. Food & Drug Administration (Dec. 13, 2018), 
    https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cGMP-questions-and-answers-guidance-industry; Data Integrity and Compliance with Drug CGMP: Questions and Answers, U.S. Dep’t of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Veterinary Medicine (Dec. 2018), available at https://www.fda.gov/media/119267/download.
    12 -  21 C.F.R. § 211.68(b).
    13 -  21 C.F.R. § 211.100(b).
    14 -  21 C.F.R. § 212.110(b).
    15 -  421 U.S. 658 (1975).
    16 -  Id. at 670.

     


    John Carney is co-leader of the BakerHostetler’s national White Collar, Investigations and Securities Enforcement and Litigation team. He is a former Securities Fraud chief, assistant United States attorney, U.S. Securities and Exchange Commission senior counsel and certified public accountant at a "Big Four" accounting firm. He is a seasoned advocate who represents public and private corporations and financial institutions in complex civil, regulatory and criminal law enforcement investigations and litigation, and advises and defends corporations and senior officers on FCPA compliance, investigation and defense.
     
    Lee Rosebush is co-leader of BakerHostetler’s FDA, Products Promotion, and Defense team and leader of the firm’s Pharmacy and Reimbursement team. He has extensive experience as a defense, regulatory, and registered patent attorney who has also worked as a registered pharmacist.



    Susrut Carpenter is a trial lawyer and former prosecutor, and a member of BakerHostetler’s National White Collar, Investigations and Securities Enforcement and Litigation team. He focuses his practice on internal investigations, white collar defense, and regulatory compliance matters, specifically in the areas of healthcare, securities, corruption, and money laundering.


     
    Andrew Serrao is an associate with BakerHostetler. He focuses his practice on bankruptcy litigation, white-collar criminal defense, anti-corruption matters and corporate investigations.

     

    Related Searches
    • Manufacturing
    • sterilization
    • cgmp compliance
    • facility

    Related Expert's Opinion

    • Solid Dosage/Creams/Ointments | Solid Dosage/Semi-solids
      PharmParts – This Makes Sense!

      PharmParts – This Makes Sense!

      5 reasons to consider purchasing secondhand parts.
      Justin Kadis, Business Development, Federal Equipment 04.06.21

    • Cold Chain Management
      Cold-Chain Handling Is Not Just a COVID Vaccine Challenge

      Cold-Chain Handling Is Not Just a COVID Vaccine Challenge

      More robust solutions for single-use cold-chain containers made with polytetrafluoroethylene fluoropolymers may be less susceptible to failure and breakage.
      Joe Cintavey, Gore PharmBIO 03.30.21

    • cGMP Manufacture | Drug Development | Scale-up/Technology Transfer
      Fast Track Automation in Pharmaceutical Manufacturing

      Fast Track Automation in Pharmaceutical Manufacturing

      Drug manufacturers turn to advanced automation technologies and project execution methodologies to reduce time, cost and risk
      Steve Zarichniak, Technical Solutions Consultant, Honeywell Process Solutions 03.25.21


    • Clinical Trials | Drug Development
      Regulatory Practices in a Post-Pandemic World

      Regulatory Practices in a Post-Pandemic World

      Envisioning the new normal for clinical development.
      Dr. Ronan Brown, SVP and Head of Integrated Global Compliance, IQVIA 03.22.21

    • Clinical Trials | Information Technology
      The Evolution of Clinical Research Technology to Support Remote Collaboration

      The Evolution of Clinical Research Technology to Support Remote Collaboration

      Pioneering change with technology advancements that yield high reward with tolerable risk.
      Angela Gill Nelms, COO for Florence Healthcare 03.11.21

    • cGMP Manufacture | Process Development | Scale-up/Technology Transfer
      Process Intensification: Understanding the Optimal Way to Maximize Productivity

      Process Intensification: Understanding the Optimal Way to Maximize Productivity

      Overcoming challenges of implementation and achieving increased volume, reduced timelines, decreased footprint, lower cost of goods, and increased flexibility.
      Priyanka Gupta, Head of Market Entry Strategy for Protein Based Therapeutics, Sartorius 03.09.21


    • Clinical Trials | Information Technology
      Data Management Trends

      Data Management Trends

      Pandemic-fueled patient centricity is creating new challenges and opportunities for data management teams.
      Deepu Joseph, Global Head & VP of Clinical Data Management 03.05.21

    • Clinical Trials | Information Technology
      Top 5 Things to Know Before Selecting Clinical Trial Technology

      Top 5 Things to Know Before Selecting Clinical Trial Technology

      Look for a future-proof model, innovative vendors - not cutting-edge technology, and focus on user-centered design and interoperability.
      Andres Garcia, Co-founder and CTO Florence 02.08.21

    • Clinical Trials
      The Future of Clinical Trials Series: Part II

      The Future of Clinical Trials Series: Part II

      Greater awareness will ensure diversity is no longer an afterthought and patients will be at the center of every aspect of clinical research.
      Jena Daniels, Rasmus Hogreffe, Ingrid Oakley-Girvan, Dr. Michelle Longmire, Medable 01.26.21


    • Clinical Trials
      The Future of Clinical Trials Series: Part I

      The Future of Clinical Trials Series: Part I

      What will 2021 have in store for an industry in flux?
      Alison Holland, Head of Decentralized Trials, Medable, Maria Fotiu, Executive Vice President of Decentralized Solutions, Syneos Health 01.19.21

    • Clinical Trials | Drug Development | Information Technology
      Virtual Clinical Trials: The Future of Dermatology Studies

      Virtual Clinical Trials: The Future of Dermatology Studies

      COVID-19 has created lasting impacts for clinical trials and a host of benefits have arisen from the adoption of virtual and hybrid models.
      Sonja VanWye, RN, MSN, Director, Dermatology Strategy, IQVIA Biotech 01.15.21

    • Clinical Trials | Drug Development
      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      The Slow – But Desperately Needed – Evolution of Oncology Clinical Development Designs

      Appropriate adaptive designs in early stages of development can accelerate timelines and reduce costs, and help focus on the most promising agents.
      Jürgen Hummel, MSc, Senior Director, Statistical Science, PPD, and Lead of PPD’s Adaptive Design Working Group 01.07.21


    • Drug Development | Industry News | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to "normalcy".
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Axinn, Veltrop & Harkrider LLP's Intellectual Property and Food and Drug Administration Practice Groups 01.05.21

    • Cold Chain Management | Logistics
      COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

      COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

      How the air cargo logistics community is embracing technology to close critical gaps in the cold chain.
      Chris Jones, EVP, Marketing and Services, Descartes 12.15.20

    • Clinical Trials | Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown, SVP of Integrated Technology & Compliance, and Joe Rymsza, VP, Global PV & Regulatory Technology Solutions, IQVIA 12.14.20

    Trending
    • Astellas, Affinivax In Global MAPS Vax Pact
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Catalent Biologics Completes Madison Expansion
    • ANI Acquires Branded Products Portfolio From Sandoz
    Breaking News
    • BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    • Microbiologics Expands Virology Services
    • ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    • Executive Moves: Novavax
    • Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Four-Week Fish Oil Regimen Showed Significant Muscular Damage Protection in Recent Study
    Review Covers Role of Vitamin K2 in the ‘Calcium Paradox’
    KD Pharma Acquires Rohner AG Manufacturing Assets
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    Shepherd Color Unveils Bismuth Vanadate Yellow Pigment
    HMG Paints Reports Positive Feedback on Contract Matt Emulsion
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BioSig Launches Software Update for PURE EP Electrophysiology Platform
    Katena Acquires Ophthalmic Surgical Instrument Maker ASICO
    Vicarious Surgical Appoints CFO and Chief Legal Officer
    Contract Pharma

    Latest Breaking News From Contract Pharma

    BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    Microbiologics Expands Virology Services
    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Cosmoprof Worldwide Bologna Postpones 2021 Show
    Native Launches Broad Spectrum SPF 30 Mineral Sunscreens
    Revieve Launches Skin Coach
    Happi

    Latest Breaking News From Happi

    BASF Increases Price of Kaolin
    Kao Launches Online Beauty Store in Europe
    Neutrogena Takes Action on Skin Health Disparities
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Maxcess updates user interface for Fife guiding Sensor
    Bobst announces virtual packaging industry event
    Edale appoints agent in Poland
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    PFNonwovens Adding New Capabilities in Znojmo
    Russ Torres Named Group President of Kimberly-Clark North America
    Aries Face Masks Meet ASTM Standards
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Biogennix Rolls Out Agilon Strip Bone Graft
    Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027
    GreenBone Ortho Closes 10 Million Euros Series B Funding Round
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations
    SUPERSMART Wins 'Best Publicly Funded Project Demonstrator' in 2021 OE-A Competition

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login